EGFR and neoplasm: Plasma miR-504 levels were significantly lower in the KRAS-mutated group than in patients with EGFR mutations (p = 0.0030 for miR-191-normalised data; p = 0.0023 for miR-16-normalised data; Fig. 4) and patients with EGFR/KRAS wild-type tumours (p = 0.0359 for miR-191-normalised data; p = 0.0054 for miR-16-normalised data; Table 3), regardless of the normalisation approach used.